Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.058
EU - Europa 3.206
AS - Asia 1.337
SA - Sud America 10
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 10.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.989
IT - Italia 998
SG - Singapore 583
DE - Germania 573
IE - Irlanda 499
SE - Svezia 380
CN - Cina 312
RU - Federazione Russa 276
HK - Hong Kong 243
UA - Ucraina 114
GB - Regno Unito 110
CA - Canada 66
FI - Finlandia 56
IN - India 56
DK - Danimarca 53
AT - Austria 47
ID - Indonesia 46
VN - Vietnam 43
FR - Francia 28
TR - Turchia 21
NL - Olanda 17
BE - Belgio 14
IR - Iran 8
JP - Giappone 7
ES - Italia 6
RO - Romania 6
BR - Brasile 5
CH - Svizzera 5
CZ - Repubblica Ceca 5
SC - Seychelles 5
CL - Cile 4
EU - Europa 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
AU - Australia 3
BG - Bulgaria 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
KR - Corea 2
LT - Lituania 2
MU - Mauritius 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
CR - Costa Rica 1
EC - Ecuador 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PL - Polonia 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 10.630
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.733
Singapore 511
Fairfield 506
Dublin 487
Frankfurt am Main 450
Chandler 367
Wilmington 344
Milan 330
Woodbridge 305
Ashburn 280
Houston 247
Hong Kong 239
New York 231
Seattle 185
Cambridge 183
Princeton 160
Santa Clara 140
Jacksonville 109
Dearborn 86
Lawrence 74
Altamura 72
Shanghai 54
San Diego 51
Vienna 47
Jakarta 46
Chicago 44
Guangzhou 40
Beijing 39
Helsinki 34
Andover 33
Nanjing 33
Rome 33
Boardman 32
London 32
Dong Ket 27
Lissone 22
Falls Church 21
Toronto 20
Pune 19
Desio 18
Kocaeli 17
Hebei 16
Monza 15
Brussels 14
Lachine 14
Ottawa 14
Tianjin 14
Jinan 13
Carate Brianza 12
Hangzhou 12
Turin 11
Edmonton 10
Florence 10
Nanchang 10
Norwalk 10
Amsterdam 9
Council Bluffs 8
Los Angeles 8
Munich 8
Redmond 8
Shenyang 8
Zhengzhou 8
Cinisello Balsamo 7
Lappeenranta 7
Potenza 7
Chengdu 6
Dallas 6
Hyderabad 6
Kunming 6
Lecco 6
Modena 6
Shenzhen 6
Torre Del Greco 6
Washington 6
Wuhan 6
Atlanta 5
Bergamo 5
Bologna 5
Capaccio 5
Cassano Magnago 5
Fremont 5
Hounslow 5
Islington 5
Legnano 5
Marietta 5
Mumbai 5
Palermo 5
Upper Marlboro 5
Brescia 4
Changsha 4
Edinburgh 4
Esslingen am Neckar 4
Leawood 4
Marano di Napoli 4
Napoli 4
Padova 4
Perugia 4
Taizhou 4
Torino 4
Ardea 3
Totale 8.126
Salva come PNG Salva come JPEG
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 392
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 302
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 294
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 246
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 234
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 230
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 230
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 229
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 227
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 210
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 207
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 200
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 188
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 187
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 182
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 177
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 175
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 174
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 165
A second update on mapping the human genetic architecture of COVID-19 164
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 161
Mapping the human genetic architecture of COVID-19 153
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 147
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 142
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 140
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 140
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 140
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 139
When progressive dysphagia could be related to an “old friend” – a case report 134
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 131
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 129
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 125
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 121
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 120
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 115
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 113
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 113
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 112
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 112
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 111
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 111
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 110
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 109
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 108
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 103
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 102
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 99
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 99
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 98
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 98
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 86
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 86
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 84
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 82
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 80
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 80
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 77
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 77
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 74
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 71
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 71
Adjuvant systemic treatment of early breast cancer: the NORA study 67
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 67
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 66
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 66
In reply to Kadri Altundag 65
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 63
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 62
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 61
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study 61
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 59
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 58
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 58
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 56
5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study 56
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 56
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? 53
Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting 52
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 50
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 50
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials 50
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab 50
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 50
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 49
Metronomic chemotherapy for advanced breast cancer patients 43
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study 43
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 41
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development 41
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 40
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 40
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 40
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 39
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 39
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 37
Breast cancer in elderly women: a different reality? Results from the NORA study 37
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study 37
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 35
Gene expression profiling in breast cancer: a clinical perspective 34
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 34
Metronomic chemotherapy 32
Totale 10.853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.179 0 0 51 53 70 94 225 212 192 124 128 30
2020/20212.513 71 208 212 204 184 236 223 359 240 210 175 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.072 252 550 162 154 121 268 132 128 96 61 82 66
2023/20241.908 81 74 65 91 251 392 345 57 167 56 65 264
2024/20251.355 251 743 361 0 0 0 0 0 0 0 0 0
Totale 11.325